A prospective randomized comparative trial showing that omeprazole prevents rebleeding in patients with bleeding peptic ulcer after successful endoscopic therapy

Hwai Jeng Lin, Wen Ching Lo, Fa Yauh Lee, Chin Lin Perng, Guan Ying Tseng

Research output: Contribution to journalArticle

228 Citations (Scopus)

Abstract

Background: A blood clot in a peptic ulcer is unstable in a low pH environment. The use of omeprazole may prevent rebleeding by elevating intragastric pH in patients with bleeding peptic ulcer after hemostasis has been achieved. Objectives: To assess the influence of using omeprazole and cimetidine on 24-hour intragastric pH and to determine their ability to prevent rebleeding after having achieved initial hemostasis in patients with active bleeding or nonbleeding visible vessels. Methods: One hundred patients with bleeding peptic ulcers who had obtained initial hemostasis were enrolled in this randomized comparative trial. In the cimetidine group (n=50), a 300- mg intravenous bolus of cimetidine was given, followed by a 1200-mg continuous infusion daily for 3 days. Thereafter, 400 mg of cimetidine was given orally twice daily for 2 months. In the omeprazole group (n=50), a 40- mg intravenous bolus of omeprazole was given, followed by 160 mg of continuous infusion daily for 3 days. Thereafter, 20 mg of omeprazole was given orally once daily for 2 months. A pH meter was inserted in each patient's fundus under fluoroscopic guidance after the intravenous bolus of cimetidine or omeprazole had been administered. Results: The stigmata of recent hemorrhage before endoscopic therapy in the omeprazole and cimetidine groups were, respectively, spurting (9 vs 12) oozing (4 vs 9), and nonbleeding visible vessel (37 vs 29) (P>.05). The duration of intragastric pH higher than 6.0 was longer in the omeprazole group (mean[±SD], 84.4%±22.9%) than that of the cimetidine group (mean[±SD], 53.5%±32.3%) (P

Original languageEnglish
Pages (from-to)54-58
Number of pages5
JournalArchives of Internal Medicine
Volume158
Issue number1
DOIs
Publication statusPublished - Jan 12 1998
Externally publishedYes

Fingerprint

Omeprazole
Peptic Ulcer
Cimetidine
Hemorrhage
Hemostasis
Therapeutics
Christianity
Thrombosis

ASJC Scopus subject areas

  • Internal Medicine

Cite this

A prospective randomized comparative trial showing that omeprazole prevents rebleeding in patients with bleeding peptic ulcer after successful endoscopic therapy. / Lin, Hwai Jeng; Lo, Wen Ching; Lee, Fa Yauh; Perng, Chin Lin; Tseng, Guan Ying.

In: Archives of Internal Medicine, Vol. 158, No. 1, 12.01.1998, p. 54-58.

Research output: Contribution to journalArticle

@article{8ea5cfbb6c1a482eab2b64dc26609e14,
title = "A prospective randomized comparative trial showing that omeprazole prevents rebleeding in patients with bleeding peptic ulcer after successful endoscopic therapy",
abstract = "Background: A blood clot in a peptic ulcer is unstable in a low pH environment. The use of omeprazole may prevent rebleeding by elevating intragastric pH in patients with bleeding peptic ulcer after hemostasis has been achieved. Objectives: To assess the influence of using omeprazole and cimetidine on 24-hour intragastric pH and to determine their ability to prevent rebleeding after having achieved initial hemostasis in patients with active bleeding or nonbleeding visible vessels. Methods: One hundred patients with bleeding peptic ulcers who had obtained initial hemostasis were enrolled in this randomized comparative trial. In the cimetidine group (n=50), a 300- mg intravenous bolus of cimetidine was given, followed by a 1200-mg continuous infusion daily for 3 days. Thereafter, 400 mg of cimetidine was given orally twice daily for 2 months. In the omeprazole group (n=50), a 40- mg intravenous bolus of omeprazole was given, followed by 160 mg of continuous infusion daily for 3 days. Thereafter, 20 mg of omeprazole was given orally once daily for 2 months. A pH meter was inserted in each patient's fundus under fluoroscopic guidance after the intravenous bolus of cimetidine or omeprazole had been administered. Results: The stigmata of recent hemorrhage before endoscopic therapy in the omeprazole and cimetidine groups were, respectively, spurting (9 vs 12) oozing (4 vs 9), and nonbleeding visible vessel (37 vs 29) (P>.05). The duration of intragastric pH higher than 6.0 was longer in the omeprazole group (mean[±SD], 84.4{\%}±22.9{\%}) than that of the cimetidine group (mean[±SD], 53.5{\%}±32.3{\%}) (P",
author = "Lin, {Hwai Jeng} and Lo, {Wen Ching} and Lee, {Fa Yauh} and Perng, {Chin Lin} and Tseng, {Guan Ying}",
year = "1998",
month = "1",
day = "12",
doi = "10.1001/archinte.158.1.54",
language = "English",
volume = "158",
pages = "54--58",
journal = "JAMA Internal Medicine",
issn = "2168-6106",
publisher = "American Medical Association",
number = "1",

}

TY - JOUR

T1 - A prospective randomized comparative trial showing that omeprazole prevents rebleeding in patients with bleeding peptic ulcer after successful endoscopic therapy

AU - Lin, Hwai Jeng

AU - Lo, Wen Ching

AU - Lee, Fa Yauh

AU - Perng, Chin Lin

AU - Tseng, Guan Ying

PY - 1998/1/12

Y1 - 1998/1/12

N2 - Background: A blood clot in a peptic ulcer is unstable in a low pH environment. The use of omeprazole may prevent rebleeding by elevating intragastric pH in patients with bleeding peptic ulcer after hemostasis has been achieved. Objectives: To assess the influence of using omeprazole and cimetidine on 24-hour intragastric pH and to determine their ability to prevent rebleeding after having achieved initial hemostasis in patients with active bleeding or nonbleeding visible vessels. Methods: One hundred patients with bleeding peptic ulcers who had obtained initial hemostasis were enrolled in this randomized comparative trial. In the cimetidine group (n=50), a 300- mg intravenous bolus of cimetidine was given, followed by a 1200-mg continuous infusion daily for 3 days. Thereafter, 400 mg of cimetidine was given orally twice daily for 2 months. In the omeprazole group (n=50), a 40- mg intravenous bolus of omeprazole was given, followed by 160 mg of continuous infusion daily for 3 days. Thereafter, 20 mg of omeprazole was given orally once daily for 2 months. A pH meter was inserted in each patient's fundus under fluoroscopic guidance after the intravenous bolus of cimetidine or omeprazole had been administered. Results: The stigmata of recent hemorrhage before endoscopic therapy in the omeprazole and cimetidine groups were, respectively, spurting (9 vs 12) oozing (4 vs 9), and nonbleeding visible vessel (37 vs 29) (P>.05). The duration of intragastric pH higher than 6.0 was longer in the omeprazole group (mean[±SD], 84.4%±22.9%) than that of the cimetidine group (mean[±SD], 53.5%±32.3%) (P

AB - Background: A blood clot in a peptic ulcer is unstable in a low pH environment. The use of omeprazole may prevent rebleeding by elevating intragastric pH in patients with bleeding peptic ulcer after hemostasis has been achieved. Objectives: To assess the influence of using omeprazole and cimetidine on 24-hour intragastric pH and to determine their ability to prevent rebleeding after having achieved initial hemostasis in patients with active bleeding or nonbleeding visible vessels. Methods: One hundred patients with bleeding peptic ulcers who had obtained initial hemostasis were enrolled in this randomized comparative trial. In the cimetidine group (n=50), a 300- mg intravenous bolus of cimetidine was given, followed by a 1200-mg continuous infusion daily for 3 days. Thereafter, 400 mg of cimetidine was given orally twice daily for 2 months. In the omeprazole group (n=50), a 40- mg intravenous bolus of omeprazole was given, followed by 160 mg of continuous infusion daily for 3 days. Thereafter, 20 mg of omeprazole was given orally once daily for 2 months. A pH meter was inserted in each patient's fundus under fluoroscopic guidance after the intravenous bolus of cimetidine or omeprazole had been administered. Results: The stigmata of recent hemorrhage before endoscopic therapy in the omeprazole and cimetidine groups were, respectively, spurting (9 vs 12) oozing (4 vs 9), and nonbleeding visible vessel (37 vs 29) (P>.05). The duration of intragastric pH higher than 6.0 was longer in the omeprazole group (mean[±SD], 84.4%±22.9%) than that of the cimetidine group (mean[±SD], 53.5%±32.3%) (P

UR - http://www.scopus.com/inward/record.url?scp=0031942244&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031942244&partnerID=8YFLogxK

U2 - 10.1001/archinte.158.1.54

DO - 10.1001/archinte.158.1.54

M3 - Article

VL - 158

SP - 54

EP - 58

JO - JAMA Internal Medicine

JF - JAMA Internal Medicine

SN - 2168-6106

IS - 1

ER -